Heart Recovery Patients Visit Capitol Hill to Advocate for Lifesaving Cardiovascular Technology
June 09 2017 - 8:08AM
Nineteen patients who benefitted from treatment with Abiomed’s
Impella heart pumps traveled to Washington, D.C. on June 8, 2017,
to meet with elected officials and participate in a Congressional
Briefing hosted by the MedTech Caucus, which supports the
development of innovative technology. This diverse group of
patients previously suffered from advanced heart failure or
cardiogenic shock due to a heart attack, and benefitted from the
help of Impella technology, the only Food and Drug
Administration-approved line of percutaneous heart pumps indicated
for those life-threatening conditions. Heart recovery is the ideal
option for patient quality of life and, as documented in several
clinical papers, has the ability to save costs for the healthcare
system1,2,3. However, Impella technology is used in only six
percent of cardiogenic shock cases and only one percent of
percutaneous coronary interventions.
Photos accompanying this announcement are available at
http://www.globenewswire.com/NewsRoom/AttachmentNg/63b87dff-59cf-40f5-b5ad-5eb5290596cb
http://www.globenewswire.com/NewsRoom/AttachmentNg/332d0cdf-0b5a-4744-ab7e-1bda6378e61f
The Congressional Briefing, “Innovation and Solutions for
Confronting Cardiovascular Disease, America’s #1 Killer,” was
hosted by the MedTech Caucus. Rep. Erik Paulsen (R-MN) and Rep.
Anna Eshoo (D-CA), Co-Chairs of the House MedTech Caucus, hosted
the event. Panel participants included: Cathy Jeon, MD,
interventional cardiologist and Director of Medical Education and
Training at Abiomed; Patrick Verta, MD, Medical Director at Edward
Lifesciences; and Jonathan R. Kaltman, MD, with the National
Institute of Health. Norm Linsky, Executive Director of the
cardiovascular patient advocacy group Mended Hearts, served as the
moderator. Treatment options in the new field of heart recovery and
heart valve disease were discussed, as well as the need for
increased screening for heart disease and preventative measures
against the disease.
“The U.S. is facing an epidemic of heart failure, which
currently affects 5.7 million Americans and is expected to grow 46
percent by the year 20304,” said Dr. Jeon. “Many people suffering
from heart failure and ischemic coronary artery disease aren’t
aware that a minimally invasive treatment option exists utilizing
the Impella® heart pumps, called a Protected PCI. At Abiomed, we
are working with hospitals and cardiovascular centers throughout
the country not only to raise awareness, but also to establish
protocols and best practices for this procedure which we believe
can improve survival, heart function and quality of life, including
a reduced number of days spent in the hospital.”
The panel also discussed the importance of minimally invasive,
cost-effective treatments, given that the American Heart
Association ranked heart conditions as the top national health
expenditure ($204 billion)5 and growing.
ABOUT IMPELLA HEART PUMPSThe Impella 2.5®,
Impella CP® and Impella 5.0® are FDA-approved heart pumps used to
treat heart attack patients in cardiogenic shock, and have the
unique ability to enable native heart recovery, allowing patients
to return home with their own hearts. The Impella 2.5 and Impella
CP devices are also approved to treat certain advanced heart
failure patients undergoing elective and urgent percutaneous
coronary interventions (PCI) such as stenting or balloon
angioplasty, to re-open blocked coronary arteries. Abiomed's
right-side heart pump, the Impella RP® device, is approved to treat
certain patients experiencing right heart failure.
To learn more about the Impella platform of heart pumps,
including their approved indications and important safety and risk
information associated with the use of the devices, please visit:
protectedpci.com.
The ABIOMED logo, ABIOMED, Impella, Impella 2.5, Impella 5.0,
Impella LD, Impella CP, Impella RP, and Recovering Hearts. Saving
Lives. are registered trademarks of ABIOMED, Inc. in the U.S. and
in certain foreign countries.
ABOUT ABIOMED Based in Danvers, Massachusetts,
Abiomed, Inc. (NASDAQ:ABMD) is a leading provider of medical
devices that provide circulatory support. Our products are designed
to enable the heart to rest by improving blood flow and/or
performing the pumping of the heart. For additional information,
please visit: abiomed.com/.
FORWARD-LOOKING STATEMENTS
This release contains forward-looking statements, including
statements regarding development of Abiomed's existing and new
products, the Company's progress toward commercial growth, and
future opportunities and expected regulatory approvals. The
Company's actual results may differ materially from those
anticipated in these forward-looking statements based upon a number
of factors, including uncertainties associated with development,
testing and related regulatory approvals, including the potential
for future losses, complex manufacturing, high quality
requirements, dependence on limited sources of supply, competition,
technological change, government regulation, litigation matters,
future capital needs and uncertainty of additional financing, and
other risks and challenges detailed in the Company's filings with
the Securities and Exchange Commission, including the most recently
filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q.
Readers are cautioned not to place undue reliance on any
forward-looking statements, which speak only as of the date of this
release. The Company undertakes no obligation to publicly release
the results of any revisions to these forward-looking statements
that may be made to reflect events or circumstances that occur
after the date of this release or to reflect the occurrence of
unanticipated events.
- Maini B, Gregory D, Scotti DJ, Buyantseva L. Percutaneous
cardiac assist devices compared with surgical hemodynamic support
alternatives: Cost-Effectiveness in the Emergent Setting. Catheter
Cardiovasc Interv. 2014 May 1;83(6):E183-92.
- Cheung A, Danter M, Gregory D. TCT-385 Comparative Economic
Outcomes in Cardiogenic Shock Patients Managed with the Minimally
Invasive Impella or Extracorporeal Life Support. J Am Coll Cardiol.
2012;60(17_S):. doi:10.1016/j.jacc.2012.08.413.
- Gregory D, Scotti DJ, de Lissovoy G, Palacios I, Dixon, Maini
B, O'Neill W. A value-based analysis of hemodynamic support
strategies for high-risk heart failure patients undergoing a
percutaneous coronary intervention. Am Health Drug Benefits. 2013
Mar;6(2):88-99.
- Mozzafarian D, Benjamin EJ, Go AS, et al. on behalf of the
American Heart Association Statistics Committee and Stroke
Statistics Subcommittee. Heart disease and stroke statistics—2016
update: a report from the American Heart Association. Circulation.
2016;133:e38-e360.
- Mozzafarian D, Benjamin EJ, Go AS, et al. on behalf of the
American Heart Association Statistics Committee and Stroke
Statistics Subcommittee. Heart disease and stroke statistics—2015
update: a report from the American Heart Association. Circulation.
2015;e230.
**For further information please contact:
Adrienne Smith
Senior Director, Public Relations and Corporate Communications
978-646-1553
adsmith@abiomed.com
Ingrid Goldberg
Director, Investor Relations
978-646-1590
igoldberg@abiomed.com
ABIOMED (NASDAQ:ABMD)
Historical Stock Chart
From Aug 2024 to Sep 2024
ABIOMED (NASDAQ:ABMD)
Historical Stock Chart
From Sep 2023 to Sep 2024